Riskpilot← Back to searchSign inGet full accessNORSE BIOTECH AS
ASActiveOrg 916210906Industrigata 23, 2406 ElverumEngineering activities and related technical consultancy · NACE 7112Est. 20153 employees
Revenue 2024
NOK 351K
-6% vs 2023
EBITDA margin
26.8%
+137% vs 2023
Equity ratio
52.4%
Financial strength
Net profit 2024
NOK -438K
+45% vs 2023
| Revenue | NOK 351K | -6% |
| EBITDA | NOK 94K | +137% |
| Net profit | NOK -438K | +45% |
| Total assets | NOK 4M | +33% |
| Equity | NOK 2,1M | +28% |
| Employees | 3 | — |
Legal name
NORSE BIOTECH AS
Org number
916210906
Legal form
Aksjeselskap
NACE code
7112 · Engineering activities and related technical consultancy
Founded
10. november 2015
Share capital
NOK 588 219
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Å utvikle, produsere, selge og markedsføre teknologier og produkter basert på biologiske råmaterialer.
Address
Industrigata 23, 2406 Elverum
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 160 | 373 | 351 |
| Staff expenses | −0 | −138 | −602 | −198 | −58 |
| EBITDA | 31 | −307 | −783 | −253 | 94 |
| Depreciation & amort. | −302 | −337 | −360 | −516 | −528 |
| EBIT | −271 | −643 | −1 143 | −769 | −434 |
| Net financials | −20 | −1 | −8 | −27 | −4 |
| Profit before tax | −291 | −644 | −1 151 | −795 | −438 |
| Tax | −125 | −219 | −0 | −0 | −0 |
| Net profit | −167 | −426 | −1 151 | −795 | −438 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 165 | 2 554 | 2 845 | 3 007 | 3 995 |
| Equity | 1 314 | 888 | −262 | 1 631 | 2 093 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 851 | 1 666 | 3 108 | 1 376 | 1 902 |
| Total debt | 851 | 1 666 | 3 108 | 1 376 | 1 902 |
EBITDA margin
26.8%
This company
15.8%
Market median
+70% vs market
20202024
Equity ratio
52.4%
This company
38.2%
Market median
+37% vs market
20202024
Return on equity
-20.9%
This company
18.4%
Market median
-214% vs market
20202024
Net profit margin
-124.6%
This company
8.1%
Market median
-1638% vs market
20202024
Asset turnover
0.09×
This company
1.12×
Market median
-92% vs market
20202024
Debt / equity
0.91×
This company
0.62×
Market median
+47% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 15% | 15% | 2022 | |
| Company | 15% | 15% | 2022 | |
| Company | 15% | 15% | 2022 | |
| Company | 15% | 15% | 2022 | |
| Individual | 15% | 15% | 2022 | |
| Individual | 15% | 15% | 2022 | |
| Company | 10% | 10% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rula Holding As
NORSE BIOTECH AS Board members of NORSE BIOTECH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Harald Ulrik Sverdrup | Board of Directors | 0 companies |
| Bjarne Kjøs | Chairman | 0 companies |
| Rune Langerud | Board of Directors | 0 companies |
| Werner Hosewinckel Christie | Board of Directors | 0 companies |
| Ray Waldo Chrisman | Board of Directors | 0 companies |
| Melvin Vernon Koch | Board of Directors | 0 companies |